FutureMeds Appoints Dr. Piotr Rozpondek, MD, PhD as Managing Director of FutureMeds Poland
Independent clinical trial management organization (SMO), FutureMeds, has appointed Dr. Piotr Rozpondek, MD, PhD as Managing Director of FutureMeds Poland. He will be responsible for strengthening FutureMeds’ presence in the country and streamlining patients' access to the latest medicine through the provision of home and virtual visits.
Dr. Piotr Rozpondek joins FutureMeds from Krakowskie Centrum Medyczne (KCM) where he held the position of Deputy Director for 4 years. After KCM was acquired by Futuremeds in 2020 he was appointed Site Director. Under his leadership, KCM has become the biggest site in FutureMeds' network driving spectacular growth for the group. His extensive experience working as a principal investigator in more than 100 clinical trials and his strong background in clinical trial management is the key to FutureMeds strategy to conclude clinical trials faster relying on a higher number of patients and enhanced data quality.
“The speed of growth in Poland for FutureMeds is fabulous and we made a decision to strengthen our management team here. Dr Piotr Rozpondek has great knowledge of the market both from an Investigator and doctor perspective as well as from his recent managerial role. He is a great candidate to manage our operation in Poland. I am sure we will experience another acceleration of our operations in Poland on his watch.”
- Dr. Radoslaw Janiak, CEO of FutureMeds
Building on KCM’s strong foundations, FutureMeds Polish teams have more than 20 years of experience conducting clinical trials in Poland. In fact, FutureMeds have delivered over 300 trials.
In 2021, more than 1000 patients chose to participate in FutureMeds’ Polish studies. FutureMeds’ Dedicated Research Sites use innovative technologies to make clinical trials available for as many patients as possible by building their awareness of existing trials.
As Managing Director of FutureMeds Poland, Piotr aims to further improve access for patients to clinical trials using virtual visits and home nursing, advance decentralized clinical trials processes, start hospital-based new sites, and introduce oncology studies to FutureMeds’ therapeutic areas.
“FutureMeds Poland is growing very rapidly and it is an honour to lead this growth from now on. We will continue to provide the highest quality services to our Patients and Sponsors due to our experience and dedication. Thanks to the use of new strategies, like virtual visits and home nursing, we plan to bring future of clinical trials to Poland today” commented Dr. Piotr Rozpondek, MD, PhD
FutureMeds is already in the top tier of Dedicated Research Site Networks in Europe. FutureMeds Dedicated Research Sites across the continent are currently involved in running clinical trials on behalf of its clients in pharma and CROs.